Literature DB >> 28368729

Reviewing Muscle Cocontraction.

Diane L Damiano1.   

Abstract

From a purely mechanical standpoint, muscle cocontraction is an inefficient utilization of muscle forces. Muscles resist each other producing little, if any, net movement. In mature gait and posture, as well as in many skilled motor activities, reciprocal activation or inhibition commonly occurs. Muscle cocontraction is frequently seen in infants and toddlers, in persons with central nervous system (CNS) damage, and interestingly, it is also seen in normal adults when they are attempting a novel complex motor skill. How might these three situations be related? This article summarizes the developmental trend of decreasing cocontraction with age. The relationship of cocontraction to motor skill development is described. Finally, the role of co contraction in movement disorders of persons with CNS deficits is explored, and an attempt is made to synthesize the presented material.

Entities:  

Year:  1993        PMID: 28368729     DOI: 10.1080/J006v12n04_02

Source DB:  PubMed          Journal:  Phys Occup Ther Pediatr        ISSN: 0194-2638            Impact factor:   2.360


  3 in total

1.  Antagonist muscle activity during reactive balance responses is elevated in Parkinson's disease and in balance impairment.

Authors:  Kimberly C Lang; Madeleine E Hackney; Lena H Ting; J Lucas McKay
Journal:  PLoS One       Date:  2019-01-25       Impact factor: 3.240

2.  Surface Electromyography Normalization Affects the Interpretation of Muscle Activity and Coactivation in Children With Cerebral Palsy During Walking.

Authors:  Yngvild Gagnat; Siri Merete Brændvik; Karin Roeleveld
Journal:  Front Neurol       Date:  2020-04-17       Impact factor: 4.003

3.  Lower Cognitive Set Shifting Ability Is Associated With Stiffer Balance Recovery Behavior and Larger Perturbation-Evoked Cortical Responses in Older Adults.

Authors:  Aiden M Payne; Jacqueline A Palmer; J Lucas McKay; Lena H Ting
Journal:  Front Aging Neurosci       Date:  2021-12-06       Impact factor: 5.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.